Navigation Links
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Date:1/8/2010

EAST BRUNSWICK, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

The Company announced that:

  • It has completed the reversion to the manufacturing processes used to manufacture its pegloticase active pharmaceutical ingredient (API) drug substance for the pivotal Phase 3 clinical trials which the Company had committed to pursue during the September 2009 Type "A" meeting as its plan to address the concerns raised by the Food and Drug Administration (FDA) in the July 31, 2009 complete response letter. Three consecutive batches of pegloticase API drug substance were manufactured in late October 2009 at the Company's third party contract manufacturer (CMO) and were then manufactured into final KRYSTEXXA drug product in November 2009. All batches were placed on stability testing by early December 2009. This manufacturing process reversion included the successful return to the PEGylation concentration utilized in the manufacture of pegloticase API for the pivotal replicate Phase 3 clinical trials.
  • The Company has received from its third party testing laboratories the majority of the in-process and final release analytical test results performed on the three consecutive batches of pegloticase API drug substance and final drug product. These analytical tests are necessary to validate these batches as being comparable to the drug product used in the Phase 3 clinical trials to establish the safety and effic
    '/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
3. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Savient Provides Update on Pegloticase BLA
6. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
7. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
8. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
9. Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc.
10. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
11. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Some 2,500 scientists and ... in Montreal for the largest ... a discipline that draws researchers from fields as far ... as diverse as designing new manufacturing processes to creating ... special time because the United Nations has declared 2014 ...
(Date:7/28/2014)...  VigeneTech, Inc, in collaboration with BioLegend, Inc., ... Software, an OEM software solution for analysis of ... offers varieties of bead-based multi-analyte immunoassay products for ... VigeneTech,s data analysis software, FCS data files can ... LEGENDplex™ software is a robust ...
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
Breaking Medicine Technology:All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 2All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 3All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 4All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 5All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 6VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... MADRID, Sept. 9 Noscira, a Grupo Zeltia (ZEL.MC) ... treat neurodegenerative diseases, has announced that the U.S. Food ... to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive ... A Phase II trial with Tideglusib (ZentylorTM) in PSP ...
... HealthSouth Corporation (NYSE: HLS ) announced today ... dividend of $16.25 per share on its 6.5% Series A ... holders of record on Oct. 1, 2010. ... rehabilitative healthcare services. Operating in 26 states across the country ...
Cached Medicine Technology:FDA Grants Fast Track Status to Tideglusib (ZentylorTM) for Progressive Supranuclear Palsy 2FDA Grants Fast Track Status to Tideglusib (ZentylorTM) for Progressive Supranuclear Palsy 3
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... heart rhythm irregularities are more likely to get a pacemaker ... fact, the study of more than 16,000 people found that ... to get a pacemaker than those without the memory-robbing condition. ... folks with dementia are so much more likely to be ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 SIMpalm ... for iOS, App is available on iTunes for download ... its kind, Audio Chef allows you to listen and cook ... the easy way: simply get out the ingredients and equipment, ... to measure or prepare ingredients ahead of time, just relax ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Oakwood ... Harris, Birkhill, Wang, Songe and Associates, PC that will ... countless tomorrows to come. , The HBWS group ... for more than $2.5 million in donations. Through their ... sponsors for the Oakwood Women’s Healthcare Classic for the ...
(Date:7/28/2014)... JOLLAWhen you,re expecting somethinglike the meal you,ve ordered ... unique electrical rhythms sweep through your brain. ... they reflect a symphony of cellsboth excitatory and ... role has been debated, gamma waves have been ... the patterns have been tied to schizophrenia, Alzheimer,s ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... sleep apnea in children, but a new study confirms that ... they,re already overweight. The researchers said that,s a concern, ... health problems -- including, ironically, sleep apnea. But they,re not ... they said, doctors and parents should be aware that a ...
Breaking Medicine News(10 mins):Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3
... contraceptive Lybrel, which is designed to eliminate monthly menstrual ... contains a lower dose of synthetic hormones in a ... days a year with no placebo pills. The usual ... consecutively, followed by seven placebo pills. ,According ...
... Jefferson Medical College have used gene therapy to reverse ... this gene therapy strategy had "unique and additive ... beta-blockers. ,Reporting in the American Heart Association ... director of the Center for Translational Medicine and the ...
... Researchers at the University of Warwick have found that sexual ... tasks such as navigating with a map in a ... of sexual orientation and withers all mens minds alike just ... worked with the BBC to collect data from over 198,000 ...
... a Californian firm has claimed to have developed super-oxidised ... ,The water, which is made by passing it ... kills bacteria, virus and fungi. ,The company ... aureus (MRSA). ,We would welcome any safe ...
... pregnancy may be exposing their baby to the risk ... study published in the journal Biological sychiatry. ... the mothers womb puts genetically susceptible children at an ... course of study, the researchers studied male and female ...
... called FGFR2 could accelerate the development of new treatments ... at Washington University School of Medicine in St. ... Trust Sanger Institute, which is part of Cambridge University; ... findings in the May 21, 2007, online version of ...
Cached Medicine News:Health News:FDA Approves Wyeth's Oral Contraceptive Lybrel 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 3Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 3
...
...
...
Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
Medicine Products: